Masters of Longevity - The Pulse

PR Newswire23 Jul 2026
AINona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases (PR New

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases

A biomedical collaboration story about a university gaining access to a transgenic mouse platform for generating fully human antibodies, useful for researchers interested in infectious disease discovery and translational antibody tools.

Key takeaways
  • H2L2 Harbour Mice ® platform and all associated intellectual property rights remain vested in Nona Biosciences.
  • Collaboration enables the inter-university Ignaz Semmelweis Institute – directed by Prof.
  • "We are delighted to partner with the Medical University of Vienna.
Fight Aging!23 Jul 2026
AIReviewing Age-Related Changes in Microglia (Fight Aging!)

Reviewing Age-Related Changes in Microglia

A review surveys how aging shifts microglial phenotypes toward chronic inflammation and explores molecular signatures, senescence, and therapeutic targeting in neurodegeneration.

Key takeaways
  • Find out how to help » Microglia are innate immune cells resident in the brain.
  • Microglia adopt different packages of behaviors, called polarizations.
  • This shift towards maladaptive inflammatory signaling and immune behavior is characteristic of aging more generally.
PR Newswire23 Jul 2026
AIAscletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd Europ

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

Preview of preclinical results showing a once-monthly co-formulated peptide combo that reduced weight more than an amylin-plus-GLP-1/GIP comparator in animals.

Key takeaways
  • ASC36_35 FDC once-monthly co-formulation is Self-Assembling Lipid Depot (SALD).
  • 62 nd EASD Annual Meeting will be held in Milan, Italy, from September 28 to October 2, 2026.
  • Data demonstrate superior weight loss to the eloralintide in combination with tirzepatide in a diet-induced obese (DIO).
Nature - Biotechnology23 Jul 2026
Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses (Nature - Biotechnology)

Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses

Discusses combinatorial in situ cancer vaccination approaches that transform tumors into antigen sources and combine adjuvants and delivery technologies to boost systemic antitumor immunity.

Key takeaways
  • Therapeutic efficacy of this approach arises from the coordinated activation of multiple immune mechanisms.
  • These innovations position in situ cancer vaccination as a patient-tailored.
  • Recent clinical investigations have underscored the therapeutic potential of in situ vaccination.